| Literature DB >> 34966347 |
Jacek Szczygielski1,2, Marta Kopańska3, Anna Wysocka4, Joachim Oertel2.
Abstract
In the past, water homeostasis of the brain was understood as a certain quantitative equilibrium of water content between intravascular, interstitial, and intracellular spaces governed mostly by hydrostatic effects i.e., strictly by physical laws. The recent achievements in molecular bioscience have led to substantial changes in this regard. Some new concepts elaborate the idea that all compartments involved in cerebral fluid homeostasis create a functional continuum with an active and precise regulation of fluid exchange between them rather than only serving as separate fluid receptacles with mere passive diffusion mechanisms, based on hydrostatic pressure. According to these concepts, aquaporin-4 (AQP4) plays the central role in cerebral fluid homeostasis, acting as a water channel protein. The AQP4 not only enables water permeability through the blood-brain barrier but also regulates water exchange between perivascular spaces and the rest of the glymphatic system, described as pan-cerebral fluid pathway interlacing macroscopic cerebrospinal fluid (CSF) spaces with the interstitial fluid of brain tissue. With regards to this, AQP4 makes water shift strongly dependent on active processes including changes in cerebral microcirculation and autoregulation of brain vessels capacity. In this paper, the role of the AQP4 as the gatekeeper, regulating the water exchange between intracellular space, glymphatic system (including the so-called neurovascular units), and intravascular compartment is reviewed. In addition, the new concepts of brain edema as a misbalance in water homeostasis are critically appraised based on the newly described role of AQP4 for fluid permeation. Finally, the relevance of these hypotheses for clinical conditions (including brain trauma and stroke) and for both new and old therapy concepts are analyzed.Entities:
Keywords: aquaporin-4; brain edema; cerebral fluid homeostasis; glymphatic system; neruovascular unit
Year: 2021 PMID: 34966347 PMCID: PMC8710539 DOI: 10.3389/fneur.2021.767470
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Figure 1Summary figure, demonstrating aquaporin-4 (AQP4) cellular trafficking as a possible target for treatment. Blue arrows represent the process of AQP4 production and relocation, the groups of potential therapeutics are labeled by red text and their impact is marked by green (enhancing) or red arrows (blocking activity). AQP4 expression (transcription of the AQP4 gene and translation of AQP4 mRNA with ribosomal production of AQP single subunits may be disturbed by small interfering RNA (siRNA), attaching selectively to AQP4 mRNA domains and preventing the translational readout. The single subunits of AQP4 are organized into orthogonal arrays of particles (OAPs) and as tetramers are transferred by endosomal vesicles to the proximity of cell membrane (predominantly in astrocytic endfoot area). Here, the AQP4 translocation to the cell surface takes place. This process relies on the activity of vanilloid-receptor-related subfamily 4 calcium channel (TRPV4) and calmodulin (CaM), directly binding to the AQP4 particles. Importantly, blocking CaM activity by trifluoperazine (TFP) was efficient against AQP4 relocation and the formation of cytotoxic brain edema. Notably, hypothermia exerts opposite action enhancing AQP4 surface exposition and this effect may be counteracted by TRPV4 inhibitors, Ca2+ chelating compounds, or CaM blockers. This effect is more relevant than the impact of hypothermia on AQP4 expression, with increased transcription reported by some, but not all relevant studies. The AQP4 channel, while integrated into astrocytic surface membrane, may be simply blocked by a number of compounds, including acetazolamide, topiramate, lamotrigine, zonisamide, acetylsulfanilamide, phenytoin, bumetanide, furosemide, tetraethylammonium, and IMD0354 as well as by heavy metal derivates or—more selectively—by TGN-020. In conditions of autoimmune response that is driven against AQP4 channels, as seen in neuromyelitis optica (NMO), blocking of antigen epitopes by monoclonal antibodies (aquaporumab), has been demonstrated as an effective NMO treatment, at least in experimental conditions. Figure created with the use of Servier Medical Art images/content of smart.servier.com in compliance with the terms of the Creative Commons Attribution 3.0 Unported Licence.